The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...

Alnylam Pharmaceuticals ALNY announced that the FDA had approved its regulatory filing seeking the label expansion of its ...

Alnylam stock jumped Friday after the drugmaker won a second Food and Drug Administration approval for its drug, Amvuttra.

Analysts' ratings for Alnylam Pharmaceuticals ALNY over the last quarter vary from bullish to bearish, as provided by 27 ...

Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...

Alnylam Pharmaceuticals gains FDA approval for Amvuttra in ATTR-CM, boosting revenue prospects. Click here to read an ...

U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...

Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA interference approach can set it apart from its peers. | Despite growing competition ...

ATTR-CM is a disease in which harmful proteins build up in the heart, making it harder to pump blood, according to the ...

Redburn Atlantic began coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research report report ...

Alnylam Pharmaceuticals Inc. won a major FDA approval on Thursday, one that could propel the Cambridge company toward a major ...

Pharmaceuticals announced moderated poster presentations of new data from the HELIOS-B Phase 3 clinical trial, which evaluated ...